Daniel P. Petrylak, MD, Talks About Importance of Mentorships in Genitourinary Oncology

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist.

CancerNetwork® spoke with Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology and co-leader of Cancer Signaling Networks at Yale Cancer Center as well as co-chair of the at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC, about and how different to field of urothelial carcinoma treatment is and how his mentor Alan Yagoda, MD, would have felt about these positive changes.


Dr. Jean Hoffman-Censits presented a case [during the conference about] a patient who has been alive several years and has received [most] forms of therapy, including chemotherapy, immunotherapy, and targeted treatments. We commented in the session that [had this been 5 years ago], the patient wouldn’t be alive today. This is one of the most exciting times for the treatment of urothelial carcinoma. I only wish that Alan Yagoda, MD, who was my mentor in this field, was still alive today. He was one of the inventors of the MVAC [methotrexate, vinblastine sulfate, doxorubicin hydrochloride, and cisplatin] regimen. At that point, that was one of the groundbreaking treatments for metastatic urothelial cancer. [There was a gap in progress] for a number of years, where we didn’t have anything that worked in the second line. Unfortunately, he can’t see today what’s going on and all the different progress that has been made, especially in the last 5 years.

Related Videos
Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.
Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.
Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Related Content